Prognostic Significance of Serum Soluble Fas Level and Its Change during Regression and Progression of Advanced Prostate Cancer

To evaluate the clinical usefulness of serum soluble Fas (sFas) and sFas ligand as a prognostic factor and for monitoring the regression and progression of metastatic prostate cancer treated with endocrine therapy, sFas and sFas ligand were measured in sera collected from 30 patients with untreated...

Full description

Saved in:
Bibliographic Details
Published in:ENDOCRINE JOURNAL 2003, Vol.50(5), pp.629-633
Main Authors: FURUYA, Yuzo, NAGAKAWA, Osamu, FUSE, Hideki
Format: Article
Language:eng ; jpn
Subjects:
Adenocarcinoma - blood
Adenocarcinoma - drug therapy
Adenocarcinoma - surgery
Aged
Aged, 80 and over
Androgen Antagonists - therapeutic use
Disease Progression
fas Receptor - blood
fas Receptor - chemistry
Gonadotropin-Releasing Hormone - analogs & derivatives
Humans
Male
Middle Aged
Orchiectomy
Population Surveillance - methods
Prognosis
Prostate cancer
Prostate-Specific Antigen - blood
Prostatic Hyperplasia - blood
Prostatic Neoplasms - blood
Prostatic Neoplasms - drug therapy
Prostatic Neoplasms - surgery
Remission Induction
sFas ligand
Solubility
Soluble Fas
Survival Analysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate the clinical usefulness of serum soluble Fas (sFas) and sFas ligand as a prognostic factor and for monitoring the regression and progression of metastatic prostate cancer treated with endocrine therapy, sFas and sFas ligand were measured in sera collected from 30 patients with untreated metastatic prostate cancer. sFas levels were measured sequentially in 16 patients who had progressed to a state of elevated prostate-specific antigen (PSA) and 5 patients who were in regression following endocrine therapy. Serum sFas levels in patients with metastatic prostate cancer were found to be significantly higher than that of control patients with benign prostate hyperplasia. Patients with low levels of serum sFas had a higher cause-specific survival rate and a higher PSA progression-free rate compared with patients with high levels of serum sFas. In patients who suffered PSA progression following endocrine therapy, serum sFas increased in parallel to the increase in PSA levels although the magnitude of change in sFas was very small. In patients whose tumor regressed following therapy, sFas levels did not change. sFas ligand levels were very low or below measurable levels in all specimens. sFas levels might be associated with poor prognosis in metastatic prostate cancer. Serum sFas ligand appears to have limited clinical relevance.
ISSN:0918-8959
1348-4540
DOI:10.1507/endocrj.50.629